Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 12/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPY4R | P50391 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | CALCA | P06881 | 2/20 | 0.56 |
| ▸ | GLP1R | P43220 | 1/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melittin SCHEMBL19458851 | 0.94 | CXCR4 (0.66) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| Melittin SCHEMBL29351537 | 0.94 | CXCR4 (0.66) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL30978816 | 0.92 | CXCR4 (0.70) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL29973066 | 0.92 | NPY1R (0.66) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL30709702 | 0.92 | NPY1R (0.66) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL29993191 | 0.91 | IL23R (0.66) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL30456690 | 0.89 | NPY2R (0.68) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29993338 | 0.88 | NPY1R (0.67) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL29989757 | 0.87 | NPY2R (0.67) | CXCR4RXFP1NPY1RNPY2RNPY4R | |
| SCHEMBL30456977 | 0.87 | NPY1R (0.66) | CXCR4NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102321-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | MARO BIO INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20250367239-A1 | COMPOSITIONS AND METHODS FOR NON-GENOTOXIC CONDITIONING | MARO BIO INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250345450-A1 | ANTIBODY-MEDIATED CONDITIONING WITH IMMUNOSUPPRESSION TO ENABLE ALLOGENEIC TRANSPLANTATION | CHILDRENS MEDICAL CT CORP (US) | 2025-11-13 | — | — | US | claimed |
| EP-4581057-A1 | COMPOSITIONS AND METHODS FOR NON-GENOTOXIC CONDITIONING | Maro Bio Inc. (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4384156-A1 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | I2Pure Corp. (US) | 2024-06-19 | — | — | EP | claimed |
| US-20240092854-A1 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | WASHINGTON UNIVERSITY | 2024-03-21 | — | — | US | claimed |
| WO-2024049839-A1 | COMPOSITIONS AND METHODS FOR NON-GENOTOXIC CONDITIONING | MARO BIO INC. (US) | 2024-03-07 | — | — | WO | claimed |
| EP-4319816-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | Centivax, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | claimed |
| EP-4196094-A1 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | I2Pure Corp. (US) | 2023-06-21 | — | — | EP | claimed |
| WO-2023019033-A1 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | I2PURE CORP. (US) | 2023-02-16 | — | — | WO | claimed |
| WO-2022217116-A1 | ANTI-VENOM ANTIBODIES AND USES THEREOF | CENTIVAX, INC. (US) | 2022-10-13 | — | — | WO | claimed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | claimed |
| WO-2022036280-A1 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | I2PURE CORP. (US) | 2022-02-17 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026102321-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | MARO BIO INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250367239-A1 | COMPOSITIONS AND METHODS FOR NON-GENOTOXIC CONDITIONING | MARO BIO INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2022036280-A1 | HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES | I2PURE CORP. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3953470-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITING | Astrazeneca AB (SE) | 2022-02-16 | — | — | EP | disclosed |
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | INBIOMOTION S.L. (ES) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220042997-A1 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE CANCER METASTASIS | MAFG, MAFK, ACP3 | CXCR4 791/4885RXFP1 2727/4885NPY1R 4376/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | CXCR4 693/4885RXFP1 125/4885NPY1R 13/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | CXCR4 1022/4885RXFP1 486/4885NPY1R 95/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | CXCR4 1022/4885RXFP1 486/4885NPY1R 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.